Cargando…

Validation of the Thai version of the family reported outcome measure (FROM-16)© to assess the impact of disease on the partner or family members of patients with cancer

BACKGROUND: Cancer not only impairs a patient’s physical and psychosocial functional behaviour, but also contributes to negative impact on family members’ health related quality of life. Currently, there is an absence of a relevant tool in Thai with which to measure such impact. The aim of this stud...

Descripción completa

Detalles Bibliográficos
Autores principales: Chantarasap, Pattariya, Johns, Nutjaree Pratheepawanit, Pairojkul, Srivieng, Sookprasert, Aumkhae, Wirasorn, Kosin, Cheawchanwattana, Areewan, Salek, Sam, Subongkot, Suphat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368697/
https://www.ncbi.nlm.nih.gov/pubmed/30736795
http://dx.doi.org/10.1186/s12955-019-1091-3
_version_ 1783394039370874880
author Chantarasap, Pattariya
Johns, Nutjaree Pratheepawanit
Pairojkul, Srivieng
Sookprasert, Aumkhae
Wirasorn, Kosin
Cheawchanwattana, Areewan
Salek, Sam
Subongkot, Suphat
author_facet Chantarasap, Pattariya
Johns, Nutjaree Pratheepawanit
Pairojkul, Srivieng
Sookprasert, Aumkhae
Wirasorn, Kosin
Cheawchanwattana, Areewan
Salek, Sam
Subongkot, Suphat
author_sort Chantarasap, Pattariya
collection PubMed
description BACKGROUND: Cancer not only impairs a patient’s physical and psychosocial functional behaviour, but also contributes to negative impact on family members’ health related quality of life. Currently, there is an absence of a relevant tool in Thai with which to measure such impact. The aim of this study was to translate and validate the Family Reported Outcome Measure (FROM-16) in Thai cancer patients’ family members. METHODS: Thai version of FROM-16 was generated by interactive forward-backward translation process following standard guidelines. This was tested for psychometric properties including reliability and validity, namely content validity, concurrent validity, known group validity, internal consistency, exploratory and confirmatory factor analysis. Construct validity was examined by comparing the Thai FROM-16 version with the WHOQOL-BREF-THAI. RESULTS: The internal consistency reliability was strong (Cronbach’s alpha = 0.86). A Negative moderate correlation between the Thai FROM-16 and WHOQOL-BREF-THAI was observed (r = − 0.4545, p < 0.00), and known group validity was proved by a statistically significant higher score in family members with high burden of care and insufficient income. The factor analysis supported both 3-factor and 2-factor loading model with slight difference when compared with the original version. CONCLUSIONS: The Thai FROM-16 showed good reliability and validity in Thai family members of patients with cancer. A slight difference in factor analysis results compared to the original version could be due to cross-culture application.
format Online
Article
Text
id pubmed-6368697
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-63686972019-02-15 Validation of the Thai version of the family reported outcome measure (FROM-16)© to assess the impact of disease on the partner or family members of patients with cancer Chantarasap, Pattariya Johns, Nutjaree Pratheepawanit Pairojkul, Srivieng Sookprasert, Aumkhae Wirasorn, Kosin Cheawchanwattana, Areewan Salek, Sam Subongkot, Suphat Health Qual Life Outcomes Research BACKGROUND: Cancer not only impairs a patient’s physical and psychosocial functional behaviour, but also contributes to negative impact on family members’ health related quality of life. Currently, there is an absence of a relevant tool in Thai with which to measure such impact. The aim of this study was to translate and validate the Family Reported Outcome Measure (FROM-16) in Thai cancer patients’ family members. METHODS: Thai version of FROM-16 was generated by interactive forward-backward translation process following standard guidelines. This was tested for psychometric properties including reliability and validity, namely content validity, concurrent validity, known group validity, internal consistency, exploratory and confirmatory factor analysis. Construct validity was examined by comparing the Thai FROM-16 version with the WHOQOL-BREF-THAI. RESULTS: The internal consistency reliability was strong (Cronbach’s alpha = 0.86). A Negative moderate correlation between the Thai FROM-16 and WHOQOL-BREF-THAI was observed (r = − 0.4545, p < 0.00), and known group validity was proved by a statistically significant higher score in family members with high burden of care and insufficient income. The factor analysis supported both 3-factor and 2-factor loading model with slight difference when compared with the original version. CONCLUSIONS: The Thai FROM-16 showed good reliability and validity in Thai family members of patients with cancer. A slight difference in factor analysis results compared to the original version could be due to cross-culture application. BioMed Central 2019-02-08 /pmc/articles/PMC6368697/ /pubmed/30736795 http://dx.doi.org/10.1186/s12955-019-1091-3 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Chantarasap, Pattariya
Johns, Nutjaree Pratheepawanit
Pairojkul, Srivieng
Sookprasert, Aumkhae
Wirasorn, Kosin
Cheawchanwattana, Areewan
Salek, Sam
Subongkot, Suphat
Validation of the Thai version of the family reported outcome measure (FROM-16)© to assess the impact of disease on the partner or family members of patients with cancer
title Validation of the Thai version of the family reported outcome measure (FROM-16)© to assess the impact of disease on the partner or family members of patients with cancer
title_full Validation of the Thai version of the family reported outcome measure (FROM-16)© to assess the impact of disease on the partner or family members of patients with cancer
title_fullStr Validation of the Thai version of the family reported outcome measure (FROM-16)© to assess the impact of disease on the partner or family members of patients with cancer
title_full_unstemmed Validation of the Thai version of the family reported outcome measure (FROM-16)© to assess the impact of disease on the partner or family members of patients with cancer
title_short Validation of the Thai version of the family reported outcome measure (FROM-16)© to assess the impact of disease on the partner or family members of patients with cancer
title_sort validation of the thai version of the family reported outcome measure (from-16)© to assess the impact of disease on the partner or family members of patients with cancer
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368697/
https://www.ncbi.nlm.nih.gov/pubmed/30736795
http://dx.doi.org/10.1186/s12955-019-1091-3
work_keys_str_mv AT chantarasappattariya validationofthethaiversionofthefamilyreportedoutcomemeasurefrom16toassesstheimpactofdiseaseonthepartnerorfamilymembersofpatientswithcancer
AT johnsnutjareepratheepawanit validationofthethaiversionofthefamilyreportedoutcomemeasurefrom16toassesstheimpactofdiseaseonthepartnerorfamilymembersofpatientswithcancer
AT pairojkulsrivieng validationofthethaiversionofthefamilyreportedoutcomemeasurefrom16toassesstheimpactofdiseaseonthepartnerorfamilymembersofpatientswithcancer
AT sookprasertaumkhae validationofthethaiversionofthefamilyreportedoutcomemeasurefrom16toassesstheimpactofdiseaseonthepartnerorfamilymembersofpatientswithcancer
AT wirasornkosin validationofthethaiversionofthefamilyreportedoutcomemeasurefrom16toassesstheimpactofdiseaseonthepartnerorfamilymembersofpatientswithcancer
AT cheawchanwattanaareewan validationofthethaiversionofthefamilyreportedoutcomemeasurefrom16toassesstheimpactofdiseaseonthepartnerorfamilymembersofpatientswithcancer
AT saleksam validationofthethaiversionofthefamilyreportedoutcomemeasurefrom16toassesstheimpactofdiseaseonthepartnerorfamilymembersofpatientswithcancer
AT subongkotsuphat validationofthethaiversionofthefamilyreportedoutcomemeasurefrom16toassesstheimpactofdiseaseonthepartnerorfamilymembersofpatientswithcancer